{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:48:32Z","timestamp":1788223712297,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T00:00:00Z","timestamp":1763251200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Neoadjuvant intense androgen deprivation therapy (ADT) with androgen receptor signaling inhibitors (ARSIs) has shown pathologic complete responses (pCR) in prostate cancer (PCa), but long\u2010term survival outcomes remain unclear. This study evaluates the durability of response following neoadjuvant ADT plus enzalutamide before robot\u2010assisted radical prostatectomy (RARP) and lymph node dissection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a secondary analysis of an open\u2010label feasibility trial enrolling men with NCCN intermediate\u2010, high\u2010, very high\u2010risk localized and regional PCa treated with 6 months of neoadjuvant ADT and enzalutamide. Factors associated with biochemical recurrence (BCR) and metastases were evaluated using appropriate univariable statistical tests, and BCR\u2010, metastasis\u2010free survival (MFS), and cancer\u2010specific survival (CSS) were estimated using the Kaplan\u2010Meier method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 39 patients enrolled, 36 patients completed all study interventions. Eighteen (66.7%) patients had NCCN very high\u2010risk disease or clinical regional lymph nodes on imaging. Four patients (11.1%) achieved pCR, although two (5.6%) developed BCR. One patient (2.8%) had M1 and three (8.3%) had N1 disease on final pathology, and all four developed metastases. Eleven (30.6%) patients received salvage therapy, with all but one receiving ADT with radiation. Factors associated with BCR included biopsy ISUP grade and positive surgical margins, while NCCN risk group, biopsy ISUP grade, perineural invasion, and pathological stage were associated with metastases (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Median follow\u2010up was 7.3 (95% CI 6.3\u20138.3) years, and the 5\u2010year BCR\u2010free survival, MFS, and CSS were 64.1%, 84.6%, and 94.3%, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Neoadjuvant enzalutamide and ADT was associated with favorable long\u2010term oncologic outcomes, supporting continued investigation in localized PCa.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.70093","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T17:01:16Z","timestamp":1763312476000},"page":"365-371","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long\u2010Term Follow\u2010Up of Neoadjuvant Enzalutamide Plus Androgen Deprivation Therapy in Localized Prostate Cancer: A Secondary Analysis of a Neoadjuvant Feasibility Trial"],"prefix":"10.1002","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-8568","authenticated-orcid":false,"given":"Braden","family":"Millan","sequence":"first","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil","family":"Pramod","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"Blachman\u2010Braun","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaskirat","family":"Saini","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Loebach","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Patel","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Gurram","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Karzai","sequence":"additional","affiliation":[{"name":"Genitourinary Malignancies Branch, National Cancer Institute Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Pinto","sequence":"additional","affiliation":[{"name":"Urologic Oncology Branch, National Cancer Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,16]]},"reference":[{"key":"e_1_2_16_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21871"},{"key":"e_1_2_16_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.08.028"},{"key":"e_1_2_16_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.6036"},{"key":"e_1_2_16_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.17.1591"},{"key":"e_1_2_16_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.4.433"},{"key":"e_1_2_16_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2023.08.005"},{"key":"e_1_2_16_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1357"},{"key":"e_1_2_16_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.53.4578"},{"key":"e_1_2_16_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01777"},{"key":"e_1_2_16_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001702"},{"key":"e_1_2_16_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2344"},{"key":"e_1_2_16_13_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0023"},{"key":"e_1_2_16_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.10.097"},{"key":"e_1_2_16_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001497"},{"key":"e_1_2_16_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2017.02.070"},{"key":"e_1_2_16_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.02.026"},{"key":"e_1_2_16_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI189900"},{"key":"e_1_2_16_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2013.46"},{"key":"e_1_2_16_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000001632"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70093","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:51:58Z","timestamp":1768035118000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.70093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,16]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/pros.70093"],"URL":"https:\/\/doi.org\/10.1002\/pros.70093","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,16]]},"assertion":[{"value":"2025-05-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}